A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[41] Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Abida, Wassim
Hahn, Andrew W.
Shore, Neal
Agarwal, Neeraj
Sieber, Paul
Smith, Matthew R.
Dorff, Tanya
Monk, Paul
Rettig, Matthew
Patel, Rupal
Page, Anne
Duff, Maureen
Xu, Rongda
Wang, Jian
Barkund, Shravani
Pankov, Aleksandr
Wang, Amber
Junttila, Melissa R.
Multani, Pratik S.
Daemen, Anneleen
Chow Maneval, Edna
Logothetis, Christopher J.
Morris, Michael J.
CLINICAL CANCER RESEARCH, 2024, 30 (06) : 1111 - 1120
[42] The role of enzalutamide in the treatment of castration-resistant prostate cancer
Rawlinson, Alex
Mohammed, Aza
Miller, Marek
Kunkler, Roger
FUTURE ONCOLOGY, 2012, 8 (09) : 1073 - 1081
[43] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
Altavilla, Amelia
Casadei, Chiara
Lolli, Cristian
Menna, Cecilia
Ravaglia, Giorgia
Gurioli, Giorgia
Farolfi, Alberto
Brighi, Nicole
Conteduca, Vincenza
Burgio, Salvatore Luca
Schepisi, Giuseppe
Rossi, Lorena
Gargiulo, Stefania
Lisotti, Ivana
De Giorgi, Ugo
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
[44] A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Graff, Julie N.
Beer, Tomasz M.
Alumkal, Joshi J.
Slottke, Rachel E.
Redmond, William L.
Thomas, George, V
Thompson, Reid F.
Wood, Mary A.
Koguchi, Yoshinobu
Chen, Yiyi
Latour, Emile
Bergan, Raymond C.
Drake, Charles G.
Moran, Amy E.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[45] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
Mahammedi, H.
Pouget, M.
Planchat, E.
Cure, H.
Durando, X.
Van-Praagh, I.
Savareux, L.
Abrial, C.
Chollet, P.
Eymard, J. C.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
[46] A multicenter Phase 1-2 study of enzalutamide in Japanese patients with castration-resistant prostate cancer (CRPC), who had received combined androgen blockade (CAB)
Akaza, H.
Uemura, H.
Tsukamoto, T.
Ozono, S.
Ogawa, O.
Sakai, H.
Oya, M.
Namiki, M.
Ohashi, Y.
Naito, S.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S704 - S704
[47] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
Verzoni, E.
Bajetta, E.
Giganti, M. O.
Guadalupi, V.
Capone, F.
Donegani, S.
Nicolai, N.
Salvioni, R.
Valdagni, R.
Procopio, G.
ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
[48] Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer
Hori, Akiyo
Sahashi, Haruka
Sano, Sora
Matsumiya, Emiri
Ariga, Maho
Asano, Akari
Soda, Midori
Goto, Chitoshi
Mizui, Takashi
Komeda, Hisao
Kitaichi, Kiyoyuki
ANTICANCER RESEARCH, 2020, 40 (12) : 7101 - 7108
[49] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
Guadalupi, V.
Giganti, M. O.
Testa, I.
Villa, S.
Nicolai, N.
Biasoni, D.
Salvioni, R.
Valdagni, R.
Bajetta, E.
Procopio, G.
ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
[50] Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
Kato, Haruo
Furuya, Yosuke
Miyazawa, Yoshiyuki
Miyao, Takeshi
Syuto, Takahiro
Nomura, Masashi
Sekine, Yoshitaka
Koike, Hidekazu
Matsui, Hiroshi
Shibata, Yasuhiro
Ito, Kazuto
Suzuki, Kazuhiro
ANTICANCER RESEARCH, 2016, 36 (11) : 6141 - 6149

← 1 2 3 4 5 →